

TRAF6 peptide TFA

Cat. No.:	HY-P3709A
Molecular Formula:	$C_{145}H_{238}N_{34}O_{44} \cdot xC_2HF_3O_2$
Sequence:	Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Glu-Ser-Ala-Ser-Gly -Pro-Ser-Glu-Asp-Pro-Ser-Val-Asn-Phe-Leu-Lys
Sequence Shortening:	AAVALLPAVLLALLAPESASGPOSEDPSVNFLK AAVALLPAVLLALLAPESASGPOSEDPSVNFLK (TFA salt)
Target:	E1/E2/E3 Enzyme; p62
Pathway:	Metabolic Enzyme/Protease; Autophagy
Storage:	Sealed storage, away from moisture and light, under nitrogen Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 100 mg/mL (Need ultrasonic)
----------	--

BIOLOGICAL ACTIVITY

Description	TRAF6 peptide TFA is a specific TRAF6-p62 inhibitor. TRAF6 peptide TFA potently abrogates NGF-dependent TrkA ubiquitination. TRAF6 peptide TFA has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke ^[1] .
-------------	---

REFERENCES

[1]. Wooten, Marie W. Substances interfering with TRAF6-p62 interaction for inhibiting intracellular aggregate formation and methods for screening for such substances. Patent WO2005050170A2.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA